The role of combined oral contraceptives in the management of acne and seborrhea

REFERENCES

• Goodman GJ. Post-acne scarring: a short review of its pathophysiology. Aust J Dermatol 2001;42:84–90
   Google Scholar
• Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cypro- terone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990;69:61–5
   PubMed Web of Science ®Google Scholar
• Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med 2001; 68: 279–86
   Google Scholar
• Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg 2001;20:144–53
   PubMed Web of Science ®Google Scholar
• Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T. Have oral contraceptives reduced the prevalence of acne? A population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology 2002;204:179–84
   PubMed Web of Science ®Google Scholar
• Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577–80
   PubMed Web of Science ®Google Scholar
• Kligman AM. Postadolescent acne in women. Cutis 1991;48:75–7
   PubMed Web of Science ®Google Scholar
• Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001;15:541–5
   PubMed Web of Science ®Google Scholar
• Burton JL, Shuster S. The relationship between sebor- rhoea and acne vulgaris. Br J Dermatol 1971;85:197–8
   PubMed Web of Science ®Google Scholar
• Pierard GE, Pierard-Franchimont C, Le T. Seborrhoea in acne-prone and acne-free patients. Dermatologica 1987;175:5–9
   PubMedGoogle Scholar
• Wellings D, Blades R, Koelink S, Keder C, Doel SV. Doctors vs. women: misconceptions on the importance of skin. Presented at 17th World Congress of Fertility and Sterility, Melbourne, 2001: 22
   Google Scholar
• Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985;20:425–9
   PubMed Web of Science ®Google Scholar
• Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U. Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology 1998;196:108–15
   PubMed Web of Science ®Google Scholar
• Kilkenny M, Merlin K, Plunkett A, Marks R. The prevalence of common skin conditions in Australian school students. 3. Acne vulgaris. Br J Dermatol 1998;139:840–5
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115:386
   Google Scholar
• Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454–8
   PubMed Web of Science ®Google Scholar
• Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instru- ment to treatment for acne vulgaris in a placebo- controlled clinical trial. Qual Life Res 1998;7:723–34
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707–13
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16
   PubMed Web of Science ®Google Scholar
• Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res 1996;5:481–90
   PubMed Web of Science ®Google Scholar
• Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol 1998;78:451–6
   PubMed Web of Science ®Google Scholar
• Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne – assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001;26:380–5
   PubMed Web of Science ®Google Scholar
• Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Qual Life Res 1996;5:131–8
   PubMed Web of Science ®Google Scholar
• Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol 2000;39:354–7
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. The psychological comorbidity in acne. Clin Dermatol 2001;19:360–63
   PubMed Web of Science ®Google Scholar
• Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001;2:135–41
   PubMedGoogle Scholar
• Madden WS, Landells ID, Poulin Y, et al. Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg 2000; 4(Suppl 1):S2–13
   Google Scholar
• Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003;206:57–67
   PubMed Web of Science ®Google Scholar
• Shaw JC. Hormonal therapy in dermatology. Dermatol Clin 2001;19:169–78
   PubMed Web of Science ®Google Scholar
• Pye RJ, Meyrick G, Pye MJ, Burton JL. Effect of oral contraceptives on sebum excretion rate. Br Med J 1977;2:1581–2
   PubMed Web of Science ®Google Scholar
• Pasquale SA. Rationale for a triphasic oral contraceptive. J Reprod Med 1984;29:560–7
   PubMedGoogle Scholar
• Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995 1:231–63
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988;38:325–32
   PubMed Web of Science ®Google Scholar
• Witkowski JA, Parish LC. From other ghosts of the past: acne lesion counting. J Am Acad Dermatol 1999; 40:131
   Google Scholar
• Lucky AW, Barber BL, Girman CJ, Williams J, Ratter- man J, Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996;35:559–65
   PubMed Web of Science ®Google Scholar
• Lucchina LC, Kollias N, Gillies R, et al. Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 1996; 35:58–63
   PubMed Web of Science ®Google Scholar
• Rizova E, Kligman A. New photographic techniques for clinical evaluation of acne. J Eur Acad Dermatol Venereol 2001; 15(Suppl 3): 13–18
   Google Scholar
• Phillips SB, Kollias N, Gillies R, Muccini JA, Drake LA. Polarized light photography enhances visualization of inflammatory lesions of acne vulgaris. J Am Acad Dermatol 1997;37:948–52
   PubMed Web of Science ®Google Scholar
• Allen BS, Smith JG, Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23–5
   PubMed Web of Science ®Google Scholar
• Burke BM, Cunliffe WJ. The assessment of acne vulgaris – the Leeds technique. Br J Dermatol 1984;111:83–92
   PubMed Web of Science ®Google Scholar
• Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979;115:571–5
   PubMed Web of Science ®Google Scholar
• Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo- controlled trial. Obstet Gynecol 1997;89:615–22
   PubMed Web of Science ®Google Scholar
• Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 1986;134:29–32
   PubMedGoogle Scholar
• Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746–54
   PubMed Web of Science ®Google Scholar
• Vartiainen M, de Gezelle H, Broekmeulen CJ. Compar- ison of the effect on acne with a combiphasic desogestrel- containing oral contraceptive and a preparation contain- ing cyproterone acetate. Eur J Contracept Reprod Health Care 2001;6:46–53
   PubMed Web of Science ®Google Scholar
• Vree ML, Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care 2001;6:108–14
   PubMed Web of Science ®Google Scholar
• Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive contain- ing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25–34
   PubMedGoogle Scholar
• Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996; 53: 163–70
   Google Scholar
• Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopau- sal Stud 1996;41:423–9
   PubMed Web of Science ®Google Scholar
• Halbe HW, de Melo NR, Bahamondes L, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998; 3:113–20
   PubMedGoogle Scholar
• Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multi- center trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception 1995; 51: 225–9
   Google Scholar
• Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen. Contraception 1992;46:477–88
   PubMed Web of Science ®Google Scholar
• Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care 2000;5:248–55
   PubMedGoogle Scholar
• Prilepskaya VN, Serov VN, Zharov EV, et al. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception 2003;68:239–45
   PubMed Web of Science ®Google Scholar
• van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2–15
   PubMedGoogle Scholar
• Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, rando- mized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38–44
   PubMed Web of Science ®Google Scholar
• Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998;57:103–9
   PubMed Web of Science ®Google Scholar
• Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol 1988;118:95–9
   PubMed Web of Science ®Google Scholar
• Fuge`re P, Percival-Smith RK, Lussier-Cacan S, Da- vignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose- response study of the estrogen component. Contraception 1990;42:225–34
   PubMed Web of Science ®Google Scholar
• Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann Endocrinol (Paris) 1999;60:157–66
   PubMed Web of Science ®Google Scholar
• Aydinlik S, Kaufman J, Lachnit-Fixson U, Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen–oestrogen combination. Clin Trials J 1990;27:392–402
   Google Scholar
• Falsetti L. Acne treatment with a new estroprogestinic biphasic combination containing desogestrel. Acta Eur Fertil 1991;22:283–6
   PubMedGoogle Scholar
• Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994;49:255–63
   PubMed Web of Science ®Google Scholar
• Pie´rard-Franchimont C, Gaspard U, Lacante P, Rhoa M, Slachmuylders P, Pierard GE. A quantitative biometro- logical assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contra- ceptive containing gestodene. Eur J Contracept Reprod Health Care 2000;5:275–86
   PubMedGoogle Scholar
• Volpe A, Silferi M, Mauri A, et al. Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur J Obstet Gynecol Reprod Biol 1994;53:205–9
   PubMed Web of Science ®Google Scholar
• Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994;50:373–82
   PubMed Web of Science ®Google Scholar
• Kasper P. Cyproterone acetate: a genotoxic carcinogen? Pharmacol Toxicol 2001;88:223–31
   PubMedGoogle Scholar
• Ohri SK, Gaer JA, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991; 67:213
   Google Scholar
• Rudiger T, Beckmann J, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet 1995;345:452–3
   PubMed Web of Science ®Google Scholar
• Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cypro- terone users. Ad hoc Committee on Androcur Users. Lancet 1994;344:1567–8
   PubMed Web of Science ®Google Scholar
• The Collaborative MILTS Project Team, Heinemann LAJ, DoMinhc T, Guggenmoos-Holzmann I, et al. Oral contraceptives and liver cancer. Results of the Multi- center International Liver Tumor Study (MILTS). Contraception 1997;56:275–84
   PubMed Web of Science ®Google Scholar
• Regidor PA, Speer K, Regidor M, Schindler EM. Long- term side-effects following cyproterone acetate contain- ing therapy in gynecology. Zentralbl Gynakol 2000;122:268–73
   PubMedGoogle Scholar
• Pymar HC, Creinin MD. The risks of oral contraceptive pills. Semin Reprod Med 2001;19:305–12
   PubMed Web of Science ®Google Scholar
• Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001;95:193–7
   PubMed Web of Science ®Google Scholar
• Gris JC, Jamin C, Benifla JL, Quere I, Madelenat P, Mares P. APC resistance and third-generation oral contraceptives: acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum Reprod 2001;16:3–8
   PubMed Web of Science ®Google Scholar
• Heinemann LA. Emerging evidence on oral contra- ceptives and arterial disease. Contraception 2000; 62: 29–36S
   Google Scholar
• Chasan-Taber L, Willett WC, Stampfer MJ, et al. Oral contraceptives and ovulatory causes of delayed fertility. Am J Epidemiol 1997;146:258–65
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–32
   PubMed Web of Science ®Google Scholar
• Smith JS, Green J, Berrington dG, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159–67
   PubMed Web of Science ®Google Scholar
• Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991;53:543–56
   Google Scholar
• Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives – findings in a large cohort study. Br J Cancer 1995;71:1340–2
   PubMed Web of Science ®Google Scholar
• Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000;152:233–41
   PubMed Web of Science ®Google Scholar
• Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxypro- gesterone acetate for contraception. Contraception 2002;65:407–10
   PubMed Web of Science ®Google Scholar
• Cobb KL, Kelsey JL, Sidney S, Ettinger B, Lewis CE. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Devel- opment in Young Adults. Osteoporos Int 2002; 13: 893–900
   Google Scholar
• Oddens BJ, Arnolds HT, Van Maris MG, Van Lunsen HW. The dynamics of oral contraceptive use in The Netherlands 1990–1993. Adv Contracept 1994;10:167–74
   PubMedGoogle Scholar